CHOnamite® Cell Line Platform

Versatile and Highly Productive Host Cell Platform for Complex Proteins

Developing a successful biotherapeutic starts with choosing the right cell line. FyoniBio’s CHOnamite® platform offers a flexible suite of CHO production cell lines, including CHO-K1, CHO-GS-KO, and CHO-DG44, designed to deliver high productivity, stability, and optimized product quality for complex proteins.

Your CHO Strategy, Customized

Different CHO cell lines can significantly influence critical quality attributes such as glycosylation, productivity, and post-translational modifications. Our CHOnamite® platform allows you to select the optimal system for each project —tailored to your molecule’s characteristics, regulatory requirements, and commercial goals.

This flexibility is particularly advantageous in biosimilar development, where selecting the right host system can improve your ability to match the originator’s quality attributes and support regulatory approval.

Our platform

The CHOnamite® Platform Supports:

Monoclonal Antibodies

Bispecific Antibodies

Biosimilars

Difficult Proteins

What Sets CHOnamite® Apart

Multiple CHO host cell lines: CHO-K1, CHO-GS-KO, CHO-DG44
High-yield expression: Achieving titers of up to 12 g/L, enhanced by our advanced transposase technology
Robust fed-batch processes: Optimized for consistent performance
Early analysis of critical quality attributes (purity, aggregation, PTMs) into the CLD process
Clone selection tailored to target glycan profiles
Fully traceable development history and documentation
Royalty-free licensing for commercial flexibility

Smart CHO Cell Line Development from Day One

By leveraging CHOnamite®, we initiate projects on a broad scale to maximize the likelihood of identifying the highest-expressing clones. Our pool generation approach integrates CHO-K1, CHO-GS-KO, and CHO-DG44 cell lines, followed by comprehensive analytical characterization, including:

• Glycan profiling
• Aggregate quantification
• Charged variant analysis
• Potency assessment

This thorough evaluation guides the selection of the most promising cell pool for state-of-the-art single-cell cloning using automated, image-based cloning technology, ensuring high monoclonality rates. This workflow increases your chances of identifying top-performing clones early—saving time and reducing risk.

Our approach is ideal for both New Biological Entities (NBEs) and Biosimilars, ensuring a balance between high productivity, biosimilarity, and desired quality attributes.

Exceptional Performance

By combining creative cell line technologies with expert-driven customization, CHOnamite® ensures superior performance, regulatory readiness, and seamless integration into biopharmaceutical manufacturing.